Unicycive Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $94.48M
- P/E (TTM)
- –
- Dividend yield
- –
About Unicycive Therapeutics
Pharmaceutical Preparations, SIC 2834
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for kidney diseases and other medical conditions. The company's pipeline includes two primary therapeutic candidates: oxylanthanum carbonate, a nanoparticle lanthanum-based phosphate binder designed for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate under development for acute kidney injury. Unicycive operates by licensing drug technologies from other pharmaceutical entities to advance them through clinical development, regulatory approval, and commercialization. Target populations include chronic kidney disease patients suffering from elevated phosphate levels and individuals with sudden kidney injury.
The company is based in the United States and maintains its principal executive offices in Mountain View, California, having previously maintained offices in Los Altos, California. Unicycive focuses its development and regulatory initiatives primarily within the United States market while seeking partnerships with global biopharmaceutical companies for commercial distribution worldwide.
Summary of the business section of Unicycive Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Unicycive Therapeutics, Inc.
- Founded
- 2016
- Headquarters
- Mountain View, CA
- Address
- 1975 W. El Camino Real, Suite 204 94040
- Phone
- (650) 384-0642
- Website
- unicycive.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRASSI & CO., CPAs, P.C., Jericho, New York
Stock & identifiers
- Ticker
- UNCY
- Exchange
- Nasdaq
- IPO date
- Jul 14, 2021
- Shares outstanding
- 28M, Aug 12, 2026
- Public float
- $64.31M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Aug 14, 2025; 1-for-10 reverse, Jun 20, 2025
- SEC CIK
- 1766140
- CUSIP
- 90466Y202
- ISIN
- US90466Y2028
- EIN
- 81-3638692
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shalabh K. Gupta | CEO, Director | 5,973,471 |
| John Townsend | CFO | – |
| Pramod Gupta | EVP, Pharmaceuticals and BD | 41,845 |
| Douglas Jermasek | EVP, Corporate Strategy | 175,012 |
| Sara Kenkare-Mitra | Director | – |
| Sandeep Laumas | Director | 105,815 |
| Gaurav Aggarwal | Director | 1,789,915 |
Employees
Headcount reported in annual reports
“As of March 30, 2026, we had 21 full-time employees”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 15, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 25, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 31, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 31, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 23, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 16, 2023 | Late filing | Notification of late filing |
| Feb 7, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 8, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 14, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 6, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |